20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Neuropace Inc (NPCE) operates in the MEDICAL DEVICES industry and is headquartered in Mountain View, United States with about 220 employees. Its market capitalization is roughly $422 million. In the fiscal year ended 2025-12-31, NPCE reported $100M in revenue and ($21M) in net income.
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy.
Interactive charts & full statements → Open the NPCE valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $99M | $100M | $80M | $65M | $46M | $45M | $41M | $37M |
| Gross Profit | $79M | $77M | $59M | $48M | $32M | $33M | $30M | $26M |
| Gross Margin % | 79.6% | 77.2% | 73.9% | 73.6% | 71.4% | 74.0% | 73.6% | 71.6% |
| Operating Income (EBIT) | ($15M) | ($16M) | ($22M) | ($27M) | ($41M) | ($24M) | ($13M) | ($22M) |
| Operating Margin % | -15.3% | -16.3% | -27.1% | -41.5% | -89.6% | -52.5% | -31.7% | -59.6% |
| Net Income | ($19M) | ($21M) | ($27M) | ($33M) | ($47M) | ($36M) | ($24M) | ($30M) |
| Net Margin % | -19.3% | -21.5% | -34.0% | -50.4% | -103.4% | -79.8% | -59.0% | -81.1% |
| EBITDA | ($12M) | ($12M) | ($17M) | ($23M) | ($37M) | ($28M) | ($12M) | ($20M) |
| Earnings Per Share (EPS) | $-0.57 | $-0.66 | $-0.93 | $-1.27 | $-1.91 | $-2.17 | $-2.19 | $-2.70 |
| Shares Outstanding (M) | 34M | 33M | 29M | 26M | 25M | 17M | 11M | 11M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $23M | $22M | $27M | $27M | $24M | $23M | $21M | $21M |
| Gross Profit | $19M | $18M | $21M | $21M | $18M | $17M | $16M | $15M |
| Gross Margin % | 82.8% | 81.8% | 77.4% | 77.4% | 77.1% | 77.0% | 75.4% | 73.2% |
| Operating Income (EBIT) | ($5M) | ($6M) | ($2M) | ($3M) | ($7M) | ($5M) | ($4M) | ($4M) |
| Operating Margin % | -22.5% | -25.2% | -6.7% | -9.5% | -29.0% | -22.9% | -17.0% | -20.2% |
| Net Income | ($6M) | ($7M) | ($3M) | ($3M) | ($9M) | ($7M) | ($5M) | ($5M) |
| Net Margin % | -27.2% | -30.3% | -10.3% | -12.8% | -36.8% | -29.2% | -24.5% | -25.9% |
| EBITDA | ($5M) | ($5M) | ($1M) | ($2M) | ($6M) | ($4M) | ($3M) | ($3M) |
| Earnings Per Share (EPS) | $-0.18 | $-0.20 | $-0.08 | $-0.11 | $-0.26 | $-0.21 | $-0.18 | $-0.19 |
| Shares Outstanding (M) | 34M | 34M | 33M | 33M | 33M | 31M | 30M | 29M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($11M) | ($11M) | ($18M) | ($20M) | ($37M) | ($25M) | ($22M) | ($25M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $1M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($12M) | ($11M) | ($18M) | ($20M) | ($37M) | ($25M) | ($22M) | ($25M) |
| FCF Margin % | -11.8% | -11.3% | -22.9% | -30.4% | -82.3% | -55.2% | -52.7% | -69.0% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($4M) | ($6M) | $1M | ($2M) | ($2M) | ($7M) | ($5M) | ($2M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($4M) | ($6M) | $0M | ($2M) | ($2M) | ($8M) | ($5M) | ($2M) |
| FCF Margin % | -17.6% | -27.3% | 1.5% | -7.2% | -9.6% | -33.4% | -22.5% | -8.7% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $97M | $106M | $95M | $108M | $114M | $134M | $56M | $21M |
| Cash & Cash Equivalents | $13M | $22M | $13M | $18M | $7M | $19M | $26M | $4M |
| Total Liabilities | $85M | $87M | $87M | $87M | $79M | $60M | $204M | $150M |
| Total Debt (Short + Long-Term) | $61M | $61M | $61M | $59M | $54M | $50M | $53M | $63M |
| Total Shareholders' Equity | $12M | $19M | $8M | $21M | $35M | $74M | ($148M) | ($129M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive NPCE viewer.
About TickerBase · Data methodology & sources · Privacy · Terms